-
-
-
-
-
-
-
Insmed (INSM) Reiterated at Buy by Stifel After TPIP P2b Trial Data
-
-
-
-
-
-
-
Insmed (INSM) PT Lowered to $162 at Evercore ISI
-
-
-
-
-
-
-
Raymond James Starts Insmed (INSM) at Outperform, 'Brinsupri Launch at Peak Performance, With Room to Breathe'
-
-
-
-
-
-
-
Insmed (INSM) halted, news pending
-
-
-
-
-
-
-
Insmed (INSM) PT Raised to $208 at Stifel: Arikayce Peak Sales Revised Upwards
-
-
-
-
-
-
-
Stifel on Insmed (INSM): Topline data disclosure removes potential NT downside risk
-
-
-
-
-
-
-
Roth/MKM Starts Insmed (INSM) at Buy
-
447,178 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

